EGFR and neoplasm: The utility of higher WSD-0922 BBB penetrance was tempered by a lower unbound concentration ratio (Figure 3E), suggesting that although more WSD-0922 is entering the brain, binding to surrounding brain tissue diminishes the concentration of free drug available to bind EGFR and other targets at the tumor site and in disseminated tumor cells.